

# Resource Summary Report

Generated by [dkNET](#) on Sep 22, 2026

## P116

RRID:CVCL\_6429

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_6429

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_6429](https://web.expasy.org/cellosaurus/CVCL_6429)

**Proper Citation:** RRID:CVCL\_6429

**Description:** Cell line P116 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Childhood T acute lymphoblastic leukemia

**Defining Citation:** [PMID:9488454](#), [PMID:20215515](#)

**Comments:** Population: Caucasian.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** P116

**Cross References:** CLO:CLO\_0008292, ATCC:CRL-2676, BioSample:SAMN03471760, cancercellines:CVCL\_6429, GDSC:1330986, GEO:GSM827152, Pharmacodb:P116\_1229\_2019, Progenetix:CVCL\_6429, TOKU-E:2820, Wikidata:Q54937222

**ID:** CVCL\_6429

**Hierarchy:** cvcl\_0367

**Record Creation Time:** 20220427T221405+0000

**Record Last Update:** 20260920T005356+0000

---

### Ratings and Alerts

No rating or validation information has been found for P116.

No alerts have been found for P116.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer cell, 41(12), 2136.

Maes T, et al. (2018) ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. Cancer cell, 33(3), 495.